Design of Novel Amphipathic α-Helical Antimicrobial Peptides with No Toxicity as Therapeutics against the Antibiotic-Resistant Gram-Negative Bacterial Pathogen,

Colin T Mant, Ziqing Jiang, Lajos Gera, Tim Davis, Robert S Hodges

Open access · diamondAbstract read

In one paragraph

Article in Journal of medicinal chemistry and drug design, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 43% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Biochemistry, Mechanistic Intricacies, and Therapeutic Potential of Antimicrobial Peptides: An Alternative to Traditional Antibiotics.Current medicinal chemistry · 2024
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Colin T MantDepartment of Biochemistry and Molecular Genetics, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Ziqing JiangDepartment of Biochemistry and Molecular Genetics, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Lajos GeraDepartment of Biochemistry and Molecular Genetics, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Tim DavisDepartment of Biochemistry and Molecular Genetics, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Robert S HodgesDepartment of Biochemistry and Molecular Genetics, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

University of Colorado Anschutz Medical Campus · US

Funding

Development of Antimicrobial Peptides to Target Gram-negative PathogensR43AI131870 · NIAID · AURORA ONCOLOGY, INC. · PI HODGES, ROBERT S · 2017 to 2017

$300k

NIAID NIH HHS R43 AI131870

6 · The paper itself

Abstract

We designed

Indexed as

Acinetobacter baumanniiAmphipathic α-helical peptidesAntimicrobial peptides (AMPs), Specificity determinantsGram-negative pathogenHemolytic activityPolar face positively charged residues (D-Lys, L-Dab and L-Dap)

Identifiers

PMID34377965

PMCPMC8351594

OpenAlexW3192073005

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.